Korean J Intern Med.  2023 Nov;38(6):787-796. 10.3904/kjim.2023.345.

Perioperative immunotherapy in stage IB-III non-small cell lung cancer: a critical review of its rationale and considerations

• Sim JK
• Choi J
• Lee SY

• KMID: 2547637
• DOI: http://doi.org/10.3904/kjim.2023.345

Abstract

Lung cancer is a dismal disease as a leading cause of overall cancer death, but the development of immune checkpoint inhibitors (ICIs) in driver gene mutation negative metastatic non-small cell lung cancer (NSCLC) is changing the paradigm of lung cancer treatment. Recently, ICIs are expanding their treatment area to early-stage NSCLC and ICIs have also changed their treatment strategies of such patients. And it is important to appropriately select patients with resectable early-stage lung cancer through a multidisciplinary team approach and decrease the tumor relapse rate in the ICIs era. In this review article, we discuss the recently released neoadjuvant and adjuvant data of ICIs, their treatment rationale, and unmet needs in the treatment of early-stage NSCLC.

Keyword

Immune checkpoint inhibitors; Neoadjuvant therapy; Adjuvant therapy; Non-small cell lung cancer